


**Automation, Automation,
Automation:**
*Keeping Up with Exponentially
Increasing Data Volume via
Compliant, In-House
Digitalisation*

10-OCT-2023

OALT

12 October 2023



Novo Nordisk

Our journey to create an in-house automation group

- Development Data Science at Novo Nordisk
- Why build an Automation Group?
- What have we built already?
- What's on our roadmap?


Views and opinions expressed are those of the speaker and not Novo Nordisk.

oalt@novonordisk.com


01 Development Data Science

DS Automation Group

Development Data Science





- 1000-strong organisation, located in DK, IN, ESP, USA
- Data Science SVP area (since 2021)
- *Data collection, curation and analysis* for **clinical trials** all under one "roof"
- **Data Science Automation Group (DSAG)** established June 2022 to coordinate, plan, develop and implement automation initiatives across the value chain



DS Automation Group

Exponential data growth leads to exponential resourcing needs




Fit 4 Take-off

- LPLV to Submission in **4 days**
- To the **4 largest markets** (USA, EU, China, Japan)
- With successful access and **launch 4 days after approval**




Our baseline - from LPLV to submission



Why build an automation group?

DS Automation Group




What is automation?

- Use of digital tools to speed up the execution of repetitive, rule-based tasks – accurately and consistently
- Depends on well-understood, well-oiled processes
- Not synonymous with AI, but AI plays an increasing role
- An essential tool to keep with our clinical ambitions!




DS Automation Group




Why automate in-house?

- It's a marathon **and** a sprint – happening at the same time!
 - "Micro solutions" to address limitations of legacy systems: reports, dashboards, reconciliation tools, etc
 - Plan process improvements around the capabilities of new systems
- *How will we be doing Clinical Data Science 5+ years from now?*



Data Science Automation Group (DSAG)

Profiles




- Specialist-led group from DM / Biostatistics, with input from IT colleagues
- **Skilled in:** R, SAS, Python, AI/ML, Power BI, etc
- **Drive automation initiatives** i.e., ideation, development, change management and solution roll out, in collaboration with LoB
- **Ensure alignment** of automation initiatives, knowledge sharing and synergies across DM and Biostat
- Maintain **short- and long-term outlook** for automation opportunities across DM and Biostat in line with corporate strategy
- **Provide status** on automation initiatives to leadership on a regular basis
- Anchored in **Clinical Analytics ART**


● Full time allocation

● Part time allocation


DS Automation Group




Product development: non-Agile



DS Automation Group




Product development: Agile



- Cross-functional teams, aligned around shared business and technology goals
- Established around organizational Value Streams
- Capabilities to define, build, validate and release solutions
- Continuous release of value by rapid release cycle: 10-12 week PI cadence

Four main value drivers of automation



-
- Creating more complex models
 - Unlocking the hidden value in our data and enabling new discoveries

-
- Breaking proportionality between # datapoints and # FTE
 - Essential to meet increasing data volumes without unsustainable growth!
 - Potentially increasing output

-
- Eliminating human error
 - Improving consistency and accuracy

-
- Reducing cycle times
 - Fit 4 Take-off

Feature requests in an ART

Ongoing



Idea (LoB)

- What is the issue?
- How many people will it benefit?
- How much value will it add?
- What systems are involved?

Dialogue (DSAG & LoB)



- **DSAG:** Ask for more details
- **DSAG:** Merge similar ideas
- **LoB & DSAG:** Sparring & Business case
- **LoB & DSAG:** Split idea into user stories

Every 10-12 weeks




Outcome (DSAG & LoB)

- Develop & Implement?
 - **LoB** will be co-owners and co-architects
- Park for later?
- Reject

Prioritisation (DSAG/BOs)




- Impact on **Speed**?
- Impact on **Efficiency**?
- Impact on **Quality**?
- Impact on **Insights**?



**What have we delivered
already?**

Safety Narratives

DS Automation Group



Safety Narratives

Business Context

- Medical writers create text-based narratives and TFLs describing patient AEs
- Requires extensive knowledge of SDTM and ADaM
- Created after DBL, i.e. on critical path wrt. F4TO

Approach

- SAS-based TFL template program
- Process re-anchored where ADaM expertise lies

Gain

- 2 days of manual work automated post-DBL
- Potentially 2 days faster to market

Status


- Tool supported OASIS 1 to F4TO submission; 17 trials in scope for extended roll-out in 2023/2024




HTA Submissions

DS Automation Group

AMNOG



Poster advertisement:



Matthew Phelps
Statistical Programming Specialist


[1] Landau Will (2021) "The targets package: a dynamic make-like function-oriented pipeline for reproducibility and high-performance computing." *Journal of Open Source Software* 4(37): 2849. <https://doi.org/10.21105/joss.02849>

What are we working on now?

Kassandra: automated test data for Fit 4 Take-Off

Kassandra


Automated test data for
Fit4Take-off



What?

- Software and processes to enable seamless flow of automated *trial-specific* test data from EDC to SDTM (submission data format), ahead of FPFV

How?



Why?

- Biostatistics programming on critical path to submission: typically not possible to do trial programming until *real* data arrives.

When?


- Technical PoC developed with external consultancy firm, June 2022
- Automation group refactoring code and extending functionality to enable organisational role out in Q4 2023

- Python engine: (i) reads study specification metadata (CSML); (ii) generates patients and populates all forms in EDC and other data models (e.g. lab data); (iii) delivers study-specific SDTM (submission format) test data to Biostat.
- Potential AI use case to make test data “realistic”

AI-enabled, Risk-Based data cleaning

Query Types


1-Dimensional data



Example: height = 5.0m

Currently automated through EDC Edit Checks


2-Dimensional data



Example: weight = 150kg, waist circumference = 26"

DSAG visualisations support DM decision making (e.g. D-VISTA)

> 2 Dimensional data




Example: subject status reconciliation across multiple forms/data sources (e.g. IWRS-EDC)



Identified through custom reports (Excel, Python, dashboards)

- Need to define what you are looking for in advance
- Manual review of visualisations/reports not scaleable to expected data loads without enormous hiring growth


AI-driven insights for DM



Supervised learning: can we spot *valuable* queries?



DS Automation Group



AI Queries Pt II: What not to query

Business context

- Want to know if a given query will impact the data or not so that we can eliminate non-value adding queries
- Saves time/resource and improves trust with sites

Approach


- Supervised learning connecting historic queries DB with EDC audit trails to identify data changed in response to queries

Challenges

- Different variables collected on different studies – difficult to define a training set which is applicable across entire trial portfolio
- Huge class imbalance: 0.4% of EDC data changes due to queries


Status

- Initial assessment of LR, RF, SVM, EEXGBoost models
- XGBoost handles class imbalance well, and adaptively selects features of relevance – but at the cost of explainability



Common fields for trials in selected therapy areas

DS Automation Group



AI Queries Pt I: Outlier detection

Business context

- Want to identify anomalies in data to guide DMs to suspected data quality issues
- Current OD strategy relies on cuts based on fixed “out of range” criteria, and subjective assessment of data visualisations (unrepeatable, unscientific)

Approach

- Framework for repeatable statistical analyses on SDTM data
- Auto-identifies correlated variables in trial SDTM dataset: beyond “hand picked” visualisations.
- Considers: univariate, bivariate, multivariate, time series outliers
- Provides explanatory text to say *why* data were flagged


Challenges

- SDTM data model far removed EDC data models – connection to historic queries DB tricky

Status

- Majority of statistical tests coded; plan to implement in visualisations framework, D-VISTA in 2024

Conclusions



- If you're not already thinking about automation, start now!
- **DS Automation Group:** specialist-led group of data scientists doing in-house digital innovation in Novo Nordisk to support clinical trials
- We maintain a short-term and long-term outlook for the needs of the DS community
- In-house automation can be *compliant* and *cost effective*
- Potential business value of solutions developed in first year:
 - *Efficiency:* >10s FTEs
 - *Speed:* potential 2 days faster to market
 - AI-enabled solutions coming to production soon (human in loop!)
- We are just getting started!!

oalt@novonordisk.com

Linked  [alasdair-p-thomson](#)